On May 2001, the Third Adult
|
|
- Patience Lee
- 5 years ago
- Views:
Transcription
1 THE RISK OF DIABETES: CAN WE IMPACT CHD THROUGH THE ATP III CHOLESTEROL GUIDELINES? * Based on a presentation given by Steven M. Haffner, MD, MPH ABSTRACT Diabetes has been recognized among diabetologists as a risk factor for coronary heart disease (CHD) for several years, and is now identified as a CHD risk factor by the Third Adult Treatment Panel (ATP III) of the National Cholesterol Education Program (NCEP). The implementation of these new guidelines into the NCEP ATP III has enlightened the general population of this risk factor and will result in a significant increase in the number of Americans who qualify for aggressive lipid-modifying therapy. The relative risk of CHD is greater in diabetic women than in diabetic men, but the CHD risk in diabetic populations in general is equivalent to CHD risk in nondiabetic populations with a history of CHD. Studies have shown that glycemic control is not sufficient to reduce the risk of CHD in diabetic populations, but it is an important part of the risk reduction plan. Patients with the metabolic syndrome appear to have greater risk for CHD than nondiabetic persons, although the risks are not as high as in diabetic patients. This shows that having several moderate risk factors can be just as detrimental as having a few, severe risk factors. All of the data support aggressive lipid modifications in diabetic patients and clinical trials have shown that the statins, fibrates, and niacin are equally effective in diabetic and nondiabetic populations. (Advanced Studies in Medicine. 2002;2(22): ) *Based on a presentation given at the 62nd Annual Meeting of the American Diabetes Association. Address correspondence to: Steven M. Haffner, MD, MPH, Professor, Department of Medicine, Division of Clinical Epidemiology, University of Texas Health Science Center at San Antonio, Texas, On May 2001, the Third Adult Treatment Panel (ATP III) of the National Cholesterol Education Program (NCEP) published their revised guidelines on the detection, evaluation, and treatment of dyslipidemia in adults. 1 Several significant changes were made since the previous set of guidelines, most notably (1) lower recommended levels of low-density lipoprotein cholesterol (LDL-C) in those at risk for coronary heart disease (CHD) and (2) the inclusion of diabetes as a risk factor for CHD. The concept of diabetes as a risk factor for CHD has been recognized in the diabetic medical community for several years (eg, sixth report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure [JNC-VI]. 2 With the NCEP ATP III (ie, outside diabetology circles), it can be considered a revolutionary concept because this recognition greatly affects the number of people needing lipid-lowering treatment. For example, the number of people qualifying for lifestyle changes is expected to be 65 million. The number of people who would qualify for both lifestyle changes and pharmacotherapy would be 36 million, which is almost 3 times the number currently prescribed a lipid-modifying drug. 3 The importance of the relationship between CHD and diabetes is best shown by the study based on data from 2 successive National Health and Nutrition Examination Survey (NHANES) populations. In this study, Gu et al reported a dramatic decline in coronary artery disease (CAD) mortality in nondiabetic patients over the course of 2 surveys ( and Vol. 2, No. 22 November 2002
2 1984). A decline is seen for diabetic men, but the effect is less significant, whereas diabetic women appear to have an increased CAD mortality. 4 These data suggest that we are not optimally managing diabetic patients and the extent of the management problem is a controversial issue. The major trials of cholesterol-modifying agents (ie, HMG-CoA reductase inhibitors [statins], fibrates, and niacin) show that these agents are as effective in diabetic as in nondiabetic populations, so the difference in CAD outcomes is not due to differences in response to pharmacotherapy. In order to optimally manage CHD in diabetes patients, it is important to remember: The risk of vascular disease is similar in diabetic subjects without pre-existing vascular disease as in nondiabetic subjects with vascular disease. Glycemic control alone will not eliminate the excess risk of CHD in diabetic subjects; however, it is nonetheless an important part of lowering CHD risk. Lipid interventions to reduce CHD are equally effective in diabetic and nondiabetic subjects. RISK OF VASCULAR DISEASE IN DIABETIC PATIENTS The relative risk of cardiovascular disease (CVD) is greater in diabetic women than diabetic men. This is true for CVD overall and its components (CHD, cardiac failure, intermittent claudication, and stroke), as shown in Figure 1. 5 It is not yet understood why there is a gender difference, but it has been suggested that glycemia may have a more adverse effect on some risk factors in women than men, especially high-density lipoprotein cholesterol (HDL-C). Howard et al showed in a study of 1846 American Indians that diabetic women were more adversely affected by certain CVD risk factors compared with diabetic men (ie, waist-to-hip ratio, HDL-C, apolipoprotein B, apolipoprotein A1, fibrinogen, and LDL size). They suggest the apparent greater negative impact of diabetes on CVD risk factors in women may explain, in part, the greater risk for CVD in diabetic women. 6 This theory bears out when analyzing the 7-year incidence of myocardial infarction (MI) in diabetic and nondiabetic populations. In a follow-up study of 1059 diabetic subjects and 1373 nondiabetic subjects, the 7-year incidence of MI for nondiabetic subjects with a history of MI was 18.8%, compared with 3.5% in nondiabetic subjects without a history of MI. In diabetic subjects with a history of MI, the incidence of MI was 45%, compared with 20% in diabetic subjects with no prior MI. When hazard ratios were calculated, the risk of death from CHD for diabetic patients without prior MI was equivalent to that associated with nondiabetic patients with a history of MI. These data provide a rationale for the aggressive treatment of CVD risk factors in diabetic patients recommended by the NCEP ATP III. 7 The current recommendation for LDL-C levels in patients with CHD is below 100 mg/dl. Given the data from this study, one can argue that diabetic patients with existing CHD should perhaps have even lower LDL-C levels, although this is not formally recommended. A large multicountry study supports the concept of increased risk for CHD in diabetic populations. The Organization to Assess Strategies for Ischemic Syndromes (OASIS) evaluated more than 8000 patients in their registry, of whom 21% (1718) had diabetes. The 2-year prognosis of the patients who were hospitalized with unstable angina or non Qwave MI was determined. Diabetic patients had significantly higher rates of coronary bypass surgery but Figure 1. Framingham Heart Study 30-Year Follow-up of CVD Events in Patients With Diabetes (Ages 35-64) Reproduced with permission from Oxford University Press, Inc. In: Hyperglycemia, Diabetes, and Vascular Diseases, edited by Neil Ruderman et al. 5 Copyright 1992 by American Physiological Society. P<.001 CVD = cardiovascular disease; CHD = coronary heart disease. Advanced Studies in Medicine 789
3 similar rates of catheterization and angioplasty as their nondiabetic counterparts. The presence of diabetes was an independent predictor of mortality, CVD, new MI, stroke, and new congestive heart failure. Importantly, diabetic women had significantly higher risk than did diabetic men, and diabetic patients without prior CVD had the same event rates, including total mortality, as the nondiabetic patients with prior CVD. 8 The concept of equivalent risk for diabetic patients and prior CHD patients has been met with some skepticism. Evans et al, in combined cross-sectional and cohort studies of the population of Tayside, Scotland, from 1988 to 1995, showed that the risk may not be equivalent for all diabetic patients. The cross-sectional study included patients between the ages of 45 and 64 years with established diabetes or established history of MI. The study identified a cohort of patients with newly diagnosed diabetes (ie, the date of diagnosis was the index date for the study) and another cohort with a recent, first hospitalization for MI (ie, their date of hospitalization was the index date for the study). In the cohort study, patients with newly diagnosed diabetes had a much lower risk of cardiovascular outcomes compared with patients who were diagnosed with recent MI (ie, established CHD). The cross-sectional study of people with established type 2 diabetes versus those with established CHD did not show the differences in risk found in other studies. 9 Diabetes is a CHD risk equivalent when applied to populations of patients, but it may not directly apply to an individual patient (eg, with newly diagnosed diabetes). In fact, Byrne and Wild have suggested that the aggressive use of statins now recommended by European and American authorities may be misguided in that decisions to treat patients with statins should not be based solely on concentrations of total cholesterol or LDL-C, but on a person s absolute risk of a vascular event. 10 Risk factors for diabetes affect the risk of diabetic microvascular complications as well. Data from the United Kingdom Prospective Diabetes Study (UKPDS) show that the incidence of MI and microvascular events increases with rising blood pressure, from 120 to 170 mm Hg (systolic); the pattern of increasing incidence for both complications is similar (Figure 2A). However, the incidence of MIs is higher than the incidence of microvascular events. 11 In early stages of diabetes, microvascular disease dominates the pattern of complications. The American Diabetes Association (ADA) recommends maintenance of blood pressure below 130/80 mm Hg. GLYCEMIC CONTROL Similarly, the UKPDS data show that blood glucose levels (HbA 1c ) in the range of 5.5% to 11% are directly proportional to the increased incidence of MI and microvascular end points (Figure 2B). Of note, the risk of MI plateaus at 9.5%, so while glucose is related to MI incidence, the overall increase is modest relative to microvascular complications. As a result, glycemic control alone is not an effective way to reduce the risk of MI. 12 The reason for this may be found in a study we conducted several years ago, in which 614 Mexican Americans were assessed for diabetes or glycemia at Figures 2A and 2B. MI and Microvascular End Points: Incidence by Mean Systolic BP and HbA 1c Concentration A Figure 2A. Reproduced with permission from BMJ Publishing Group. BMJ, 2000; 32(7258): Figure 2B. Reproduced with permission from BMJ Publishing Group. BMJ. 2000; 32(7258): MI indicates myocardial infarction; BP, blood pressure. B 790 Vol. 2, No. 22 November 2002
4 baseline and again after 8 years of follow-up. Specific cardiovascular risk factors were noted as well, to determine if prediabetic individuals might have a pattern of cardiovascular risk factors (ie, before diabetes onset) that may explain the lack of association between glycemic severity or disease duration and macrovascular complications. The results showed that those who were not diabetic at baseline but developed diabetes by the 8-year follow-up had significantly higher levels of LDL-C, triglycerides (TG), fasting glucose and insulin, 2-hour glucose, body mass index, and blood pressure. By contrast, levels of HDL-C were lower compared with participants who remained nondiabetic. This pattern persisted even when those with impaired glucose tolerance at baseline were not considered. We hypothesized that hyperinsulinemia and insulin resistance preceded the onset of type 2 diabetes. 13 The pattern of lipid and glucose changes is characteristic of the prediabetic state. In fact, longitudinal studies of diabetic patients show that TG levels increase when people become diabetic, but HDL-C levels remain the same. A very recent study from the Nurses Health Study database (ie, more than women) showed a substantially elevated risk of CVD in women before clinical diagnosis of diabetes, again suggesting that aggressive management of cardiovascular risk factors is warranted in individuals at increased risk for diabetes. 14 The UKPDS study ranked the specific CVD risk factors in diabetic patients in the following order of importance regarding treatment: LDL-C, HDL-C, HbA 1c, systolic blood pressure, and smoking. 15 For many years, the focus of treatment was on fibrates to affect HDL-C levels. However, despite the relatively normal levels of LDL-C in diabetic patients, the composition of LDL is altered and LDL-C is a very strong risk factor for CHD. This realization was critical in creating the ADA position paper in ,17 LIPID INTERVENTIONS A comparison of the results from the major primary and secondary prevention trials shows that statins are equally effective in diabetic and nondiabetic subjects in affecting lipid profiles and CHD risk reduction (Table 1) They are discussed elsewhere in this issue by Drs Leiter and Tuomilehto. ADA GUIDELINES ON LIPID MANAGEMENT Given the identification of diabetes as a CHD risk factor and the recommended target LDL-C of below 100 mg/dl in those with a CHD risk factor, the NCEP ATP III guidelines recommend the following treatment options, depending on LDL-C level 1 : LDL-C >130 mg/dl: simultaneously initiate therapeutic lifestyle change (TLC) and LDL-lowering drugs, which are generally statins. LDL-C mg/dl: intensify statin therapy and TLC; add drug to modify atherogenic dyslipidemia (fibrate or nicotinic acid). If TG levels are 200 mg/dl after the LDL-C goal is met, non HDL-C goal is <130 mg/dl. [Non-HDL-C targets are calculated by adding 30 to the standard ATP III target LDL-C level.] 24 The primary targets may need to be revised based on recent results from the Heart Protection Study, in Table 1. CHD Prevention Trials With Statins in Diabetic Subjects: Subgroup Analysis CHD Risk CHD Risk Reduction Reduction Study Drug (dose) n (Overall) (Diabetes) 1 Prevention AFCAPS/TexCAPS 20 Lovastatin % -43% (NS) HPS 23 Simvastatin % -26% (P<.00001)* 2 Prevention CARE 21 Pravastatin % -25% (P=.05) 4S 19 Simvastatin % -55% (P=.002) LIPID 18 Pravastatin % -19% (NS) 4S Reanalysis 22 Simvastatin % -42% (P=.001) HPS 23 Simvastatin % -26% (P<.00001)* *Overall results for diabetic subgroup. CHD = coronary heart disease; AFCAPS/TexCAPS = Air Force/Texas Coronary Atherosclerosis Prevention Study; HPS = Heart Prevention Study; CARE = Cholesterol and Recurrent Events Trial; 4S = Scandinavian Simvastatin Survival Study; LIPID = Long- Term Intervention with Pravastatin in Ischaemic Disease; NS = Not significant. Advanced Studies in Medicine 791
5 which baseline LDL-C levels were not related to the response to lipid-modifying drugs. Therefore, patients with very low LDL-C levels at baseline can still benefit from LDL-C reduction. 23,25 THE METABOLIC SYNDROME The NCEP ATP III also defined the metabolic syndrome a cluster of criteria that increase the risk of developing diabetes and therefore, CVD. As shown in Table 2, possessing 3 or more of the defined criteria qualifies a patient as having the metabolic syndrome. 1 Note that many of the risk factors are set at lower cutoff points than the NCEP ATP III recommended cutoff points. Therefore, having many risk factors can be as detrimental as having fewer, more severe risk factors. Not surprisingly, CHD appears to be more prevalent in metabolic syndrome patients than in nondiabetic patients, but less prevalent than in diabetic patients. 24 Thus, the metabolic syndrome might not be viewed as an equivalent to diabetes or CHD, but controlling the metabolic syndrome is a primary prevention of high-risk factors. Approximately 85% of diabetic patients have the metabolic syndrome, and those patients also have twice the prevalence of CHD as diabetic patients without the metabolic syndrome. So, if cost is an issue in terms of aggressively treating dyslipidemia in diabetic patients, those with type 2 diabetes and the metabolic syndrome should receive higher priority for treatment than those without the metabolic syndrome. CONCLUSION Recent data now support aggressive treatment of LDL-C in diabetic patients, given that their risk of vascular disease is equivalent to the risk in nondiabetic patients with a history of vascular disease; the NCEP ATP III guidelines provide a useful framework on which to build a treatment strategy. Reducing or eliminating the epidemic of CVD among diabetic patients will require a variety of approaches, including glycemic control; prevention of type 2 diabetes; aggressive treatment of CVD risk factors; and innovative agents that lower blood sugar as well as affect cardiovascular risk factors and insulin resistance. Table 2. NCEP ATP III:The Metabolic Syndrome Diagnosis Is Established When 3 of These Risk Factors Are Present Risk Factor Abdominal obesity (Waist circumference) Men Women TG HDL-C Men Women Blood pressure Fasting glucose Defining Level >40 in >35 in 150 mg/dl <40 mg/dl <50 mg/dl 130/ 85 mm Hg 110 mg/dl Data from Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA. 2001;285: NCEP ATP III = National Cholesterol Education Program Third Adult Treatment Panel; TG = triglycerides; HDL-C = High-density lipoprotein cholesterol. REFERENCES 1. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285: The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157: Grundy SM, Cleeman JL, Rifkind BM, Kuller LH. Cholesterol lowering in the elderly population: Coordinating Committee of the National Cholesterol Education Program. Arch Intern Med. 1999;159: Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA. 1999;281: Wilson PWF, Kannel WB. Epidemiology of hyperglycemia and atherosclerosis. In: Ruderman N, Williamson J, Brownlee M, eds. Hyperglycemia, Diabetes and Vascular Disease. New York, NY:Oxford University Press; Howard BV, Cowan LD, Go O, Welty TK, Robbins DC, Lee ET. Adverse effects of diabetes on multiple cardiovascular disease risk factors in women. The Strong Heart Study. Diabetes Care. 1998;21: Vol. 2, No. 22 November 2002
6 7. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339: Malmberg K, Yusuf S, Gerstein HC, et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation. 2000;102: Evans JM, Wang J, Morris AD. Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross-sectional and cohort studies. BMJ. 2002;324: Byrne CD, Wild SH. Diabetes care needs evidence-based interventions to reduce risk of vascular disease. BMJ. 2000;320: Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321: Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321: Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA. 1990; 263: Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willett WC, Manson JE. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care. 2002;25: Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS 23). BMJ. 1998;316: American Diabetes Association. Clinical practice recommendations. Diabetes Care. 2000;23(suppl1):S32-S Haffner SM. Management of dyslipidemia in adults with diabetes. Diabetes Care.1998;21: The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339: Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 1997; 20: Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/ TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279: Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The CARE Investigators. Circulation. 1998;98: Haffner SM, Alexander CM, Cook TJ, et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med. 1999;159: MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience. Eur Heart J. 1999;20: Hirsch GA, Vaid N, Blumenthal RS. Perspectives: The significance of measuring non-hdl-cholesterol. Prev Cardiol 2002;5(3): Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebocontrolled trial. Lancet. 2002;360: Advanced Studies in Medicine 793
Cardiovascular disease (CVD) is the
Epidemiology/Health Services/Psychosocial Research O R I G I N A L A R T I C L E Cost Effectiveness of Statin Therapy for the Primary Prevention of Major Coronary Events in Individuals With Type 2 Diabetes
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationAlthough medical advances have curbed
PREVENTION OF CORONARY HEART DISEASE IN THE METABOLIC SYNDROME AND DIABETES MELLITUS * Sherita Hill Golden, MD, MHS ABSTRACT The leading cause of death in patients with diabetes is cardiovascular disease.
More informationThe American Diabetes Association estimates
DYSLIPIDEMIA, PREDIABETES, AND TYPE 2 DIABETES: CLINICAL IMPLICATIONS OF THE VA-HIT SUBANALYSIS Frank M. Sacks, MD* ABSTRACT The most serious and common complication in adults with diabetes is cardiovascular
More informationIschemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More informationHyperlipidemia and Cardiovascular Risk Factors in Patients With Type 2 Diabetes
...PRESENTATIONS... Hyperlipidemia and Cardiovascular Risk Factors in Patients With Type 2 Diabetes Based on a presentation by Ronald B. Goldberg, MD Presentation Summary Atherosclerosis accounts for approximately
More informationNew Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines
Clin. Cardiol. Vol. 26 (Suppl. III), III-19 III-24 (2003) New Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines H. BRYAN BREWER, JR, M.D. Molecular
More information( Diabetes mellitus, DM ) ( Hyperlipidemia ) ( Cardiovascular disease, CVD )
005 6 69-74 40 mg/dl > 50 mg/dl) (00 mg/dl < 00 mg/dl(.6 mmol/l) 30-40% < 70 mg/dl 40 mg/dl 00 9 mg/dl fibric acid derivative niacin statin fibrate statin niacin ( ) ( Diabetes mellitus,
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationEugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG
Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System
More informationThe Metabolic Syndrome: Is It A Valid Concept? YES
The Metabolic Syndrome: Is It A Valid Concept? YES Congress on Diabetes and Cardiometabolic Health Boston, MA April 23, 2013 Edward S Horton, MD Joslin Diabetes Center Harvard Medical School Boston, MA
More informationOptimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden
Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Cardiovascular Disease Prevention (CVD) Three Strategies for CVD
More informationElevated Risk of Cardiovascular Disease Prior to Clinical Diagnosis of Type 2 Diabetes
Epidemiology/Health Services/Psychosocial Research O R I G I N A L A R T I C L E Elevated Risk of Cardiovascular Disease Prior to Clinical Diagnosis of Type 2 Diabetes FRANK B. HU, MD 1,2,3 MEIR J. STAMPFER,
More informationPreventing Myocardial Infarction in the Young Adult in the First Place: How Do the National Cholesterol Education Panel III Guidelines Perform?
Journal of the American College of Cardiology Vol. 41, No. 9, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Inc. doi:10.1016/s0735-1097(03)00187-6
More informationMedical evidence suggests that
COMBINATION THERAPY TO ACHIEVE LIPID GOALS David G. Robertson, MD* ABSTRACT Coronary heart disease (CHD) remains the leading cause of death in the United States despite recent advances in treatment and
More informationNearly 62 million people in the. ... REPORTS... New Therapeutic Options in the National Cholesterol Education Program Adult Treatment Panel III
... REPORTS... New Therapeutic Options in the National Cholesterol Education Program Adult Treatment Panel III Robert L. Talbert, PharmD Abstract Coronary heart disease (CHD) is a common, costly, and undertreated
More informationAtherosclerotic Disease Risk Score
Atherosclerotic Disease Risk Score Kavita Sharma, MD, FACC Diplomate, American Board of Clinical Lipidology Director of Prevention, Cardiac Rehabilitation and the Lipid Management Clinics September 16,
More informationRECOGNITION OF THE METABOLIC SYNDROME
THE METABOLIC SYNDROME IN CLINICAL PRACTICE Michael H. Davidson, MD* ABSTRACT Patients with the metabolic syndrome remain at significantly elevated risk of morbidity and mortality associated with coronary
More informationThe updated guidelines from the National
BEYOND NCEP ATP III: LESSONS LEARNED AND FUTURE DIRECTIONS * Benjamin J. Ansell, MD, FACP ABSTRACT The National Cholesterol Education Program (NCEP) Third Adult Treatment Panel (ATP III) guidelines provide
More informationThreshold Level or Not for Low-Density Lipoprotein Cholesterol
... SYMPOSIA PROCEEDINGS... Threshold Level or Not for Low-Density Lipoprotein Cholesterol Based on a debate between Philip J. Barter, MD, PhD, FRACP, and Frank M. Sacks, MD Debate Summary As drugs, such
More informationIt is currently estimated that diabetes prevalence by
clinical Study The Prevalence and Pattern of Dyslipidemia among Type 2 Diabetic Patients at Rural Based Hospital in Gujarat, India Hetal Pandya*, JD Lakhani**, J Dadhania, A Trivedi Abstract Only proper
More informationHow to Reduce CVD Complications in Diabetes?
How to Reduce CVD Complications in Diabetes? Chaicharn Deerochanawong M.D. Diabetes and Endocrinology Unit Department of Medicine Rajavithi Hospital, Ministry of Public Health Framingham Heart Study 30-Year
More informationThe Diabetes Link to Heart Disease
The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More informationDiabetic Dyslipidemia
Diabetic Dyslipidemia Dr R V S N Sarma, M.D., (Internal Medicine), M.Sc., (Canada), Consultant Physician Cardiovascular disease (CVD) is a significant cause of illness, disability, and death among individuals
More informationPIEDMONT ACCESS TO HEALTH SERVICES, INC. Guidelines for Screening and Management of Dyslipidemia
PIEDMONT ACCESS TO HEALTH SERVICES, INC. Policy Number: 01-09-021 SUBJECT: Guidelines for Screening and Management of Dyslipidemia EFFECTIVE DATE: 04/2008 REVIEWED/REVISED: 04/12/10, 03/17/2011, 4/10/2012,
More informationMetformin should be considered in all patients with type 2 diabetes unless contra-indicated
November 2001 N P S National Prescribing Service Limited PPR fifteen Prescribing Practice Review PPR Managing type 2 diabetes For General Practice Key messages Metformin should be considered in all patients
More informationMOLINA HEALTHCARE OF CALIFORNIA
MOLINA HEALTHCARE OF CALIFORNIA HIGH BLOOD CHOLESTEROL IN ADULTS GUIDELINE Molina Healthcare of California has adopted the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel
More information4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for
+ Update on Lipid Management Stacey Gardiner, MD Assistant Professor Division of Cardiovascular Medicine Medical College of Wisconsin + The stats on heart disease Over the past 10 years for which statistics
More informationGUIDELINES FOR DYSLIPIDEMIA MANAGEMENT AND EDUCATION THROUGH NOVA SCOTIA DIABETES CENTRES
GUIDELINES FOR DYSLIPIDEMIA MANAGEMENT AND EDUCATION THROUGH NOVA SCOTIA DIABETES CENTRES Prepared by DCPNS Action Committee Dr. Lynne Harrigan Brenda Cook Peggy Dunbar Bev Harpell with the assistance
More informationCoronary heart disease (CHD) has. Clearfield The National Cholesterol Education Program Adult Treatment Panel III guidelines
the osteopathic physician. The treatment approach involves therapeutic lifestyle changes with diet, exercise, and weight loss. It requires regular, careful monitoring of serum cholesterol levels. The new
More informationCardiovascular Risk Reduction and Other Co-morbidities in Type 2 Diabetes
Cardiovascular Risk Reduction and Other Co-morbidities in Type 2 Diabetes Following this presentation, you will be able to: Describe the relationship between major CV risk factors and CVD outcomes Select
More informationThe Framingham Coronary Heart Disease Risk Score
Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk Score Michelle A. Albert, MD, MPH; Robert J. Glynn, PhD; Paul M Ridker, MD, MPH Background Although
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationORIGINAL INVESTIGATION. The Impact of Diabetes Mellitus on Mortality From All Causes and Coronary Heart Disease in Women
The Impact of Mellitus on Mortality From All Causes and Coronary Heart Disease in Women 20 Years of Follow-up ORIGINAL INVESTIGATION Frank B. Hu, MD; Meir J. Stampfer, MD; Caren G. Solomon, MD; Simin Liu,
More informationEstablished Risk Factors for Coronary Heart Disease (CHD)
Getting Patients to Make Small Lifestyle Changes That Result in SIGNIFICANT Improvements in Health - Prevention of Diabetes and Obesity for Better Health Maureen E. Mays, MD, MS, FACC Director ~ Portland
More informationStatins in the Treatment of Type 2 Diabetes Mellitus: A Systematic Review.
ISPUB.COM The Internet Journal of Cardiovascular Research Volume 7 Number 1 Statins in the Treatment of Type 2 Diabetes Mellitus: A Systematic Review. C ANYANWU, C NOSIRI Citation C ANYANWU, C NOSIRI.
More informationApplicability of Cholesterol-Lowering Primary Prevention Trials to a General Population
Applicability of Cholesterol-Lowering Primary Prevention Trials to a General Population The Framingham Heart Study ORIGINAL INVESTIGATION Donald M. Lloyd-Jones, MD; Christopher J. O Donnell, MD, MPH; Ralph
More informationCoronary artery disease remains the leading
UNMET NEEDS IN THE TREATMENT OF ATHEROSCLEROSIS: WHY ARE WE NOT DONE YET? * Evan A. Stein, MD, PhD ABSTRACT Heart disease remains the leading cause of death in the United States. Despite advances in surgical,
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationDiabetes Day for Primary Care Clinicians Advances in Diabetes Care
Diabetes Day for Primary Care Clinicians Advances in Diabetes Care Elliot Sternthal, MD, FACP, FACE Chair New England AACE Diabetes Day Planning Committee Welcome and Introduction This presentation will:
More informationStatin Therapy in the Management of Diabetes Mellitus; How Relevant?
American Medical Journal 4 (1): 36-42, 2013 ISSN 1949-0070 2013 doi:10.3844/amjsp.2013.36.42 Published Online 4 (1) 2013 (http://www.thescipub.com/amj.toc) Statin Therapy in the Management of Diabetes
More informationComparison of Original and Generic Atorvastatin for the Treatment of Moderate Dyslipidemic Patients
Comparison of Original and Generic Atorvastatin for the Treatment of Moderate Dyslipidemic Patients Cardiology Department, Bangkok Metropolitan Medical College and Vajira Hospital, Bangkok, Thailand Abstract
More informationMetabolic Syndrome: Why Should We Look For It?
021-CardioCase 29/05/06 15:04 Page 21 Metabolic Syndrome: Why Should We Look For It? Dafna Rippel, MD, MHA and Andrew Ignaszewski, MD, FRCPC CardioCase presentation Andy s fatigue Andy, 47, comes to you
More informationI t is well established that non-insulin dependent diabetes is
1398 CARDIOVASCULAR MEDICINE Cardiovascular disease incidence and mortality in older men with diabetes and in men with coronary heart disease S G Wannamethee, A G Shaper, L Lennon... See end of article
More informationMetabolic Syndrome among Type-2 Diabetic Patients in Benghazi- Libya: A pilot study. Arab Medical University. Benghazi, Libya
Original Article Metabolic Syndrome among Type-2 Diabetic Patients in Benghazi- Libya: A pilot study Alshkri MM 1, Elmehdawi RR 2 1 Benghazi Diabetes Center. 2 Medical Department, Faculty of Medicine,
More informationAccelerated atherosclerosis begins years prior to the diagnosis of diabetes
Joslin Diabetes Forum 211: Optimizing Care for the Practicing Clinician Risk for atherosclerosis is 2 4 times greater in patients with diabetes CVD accounts for 65% of diabetic mortality >5% of patients
More informationDiabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology
Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology Disclosures In compliance with the accrediting board policies, the American Diabetes Association requires the
More informationWelcome and Introduction
Welcome and Introduction This presentation will: Define obesity, prediabetes, and diabetes Discuss the diagnoses and management of obesity, prediabetes, and diabetes Explain the early risk factors for
More informationSince the release of the National Cholesterol PROCEEDINGS FUTURE DIRECTIONS IN DYSLIPIDEMIA MANAGEMENT * Michael B. Clearfield, DO, FACOI ABSTRACT
FUTURE DIRECTIONS IN DYSLIPIDEMIA MANAGEMENT * Michael B. Clearfield, DO, FACOI ABSTRACT Since the National Cholesterol Education Program (NCEP) Third Adult Treatment Panel (ATP III) guidelines, 3 large
More informationManagement of Cardiovascular Disease in Diabetes
Management of Cardiovascular Disease in Diabetes Radha J. Sarma, MBBS, FACP. FACC. FAHA. FASE Professor of Internal Medicine Western University of Health Sciences. Director, Heart and Vascular Center Western
More informationHow much do we pay for a benefit? A Descriptive Cost Analysis of the Use of Statins. The Need for a National Cost- Effectiveness Analysis
Point of View How much do we pay for a benefit? A Descriptive Cost Analysis of the Use of Statins. The Need for a National Cost- Effectiveness Analysis José Luiz da Costa Vieira, Vera Lúcia Portal, Emílio
More informationLIST OF ABBREVIATIONS
Diabetes & Endocrinology 2005 Royal College of Physicians of Edinburgh Diabetes and lipids 1 G Marshall, 2 M Fisher 1 Research Fellow, Department of Cardiology, Glasgow Royal Infirmary, Glasgow, Scotland,
More informationHyperlipidemia: Lowering the Bar on the Lipid Limbo. Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH
Mark slides Hyperlipidemia: Lowering the Bar on the Lipid Limbo Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH Hyperlipidemia is a common problem Nearly 50% of men in the
More informationBehind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL
Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL Sung-Joon Lee, PhD Division of Food Science Institute of Biomedical Science and Safety Korea University Composition of Lipoproteins:
More informationThe metabolic syndrome, also called
Metabolic Syndrome/Insulin Resistance Syndrome/Pre-Diabetes O R I G I N A L A R T I C L E Reduction of Cardiovascular Events by Simvastatin in Nondiabetic Coronary Heart Disease Patients With and Without
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationData Alert. Vascular Biology Working Group. Blunting the atherosclerotic process in patients with coronary artery disease.
1994--4 Vascular Biology Working Group www.vbwg.org c/o Medical Education Consultants, LLC 25 Sylvan Road South, Westport, CT 688 Chairman: Carl J. Pepine, MD Eminent Scholar American Heart Association
More informationEpidemiology of Diabetes, Impaired Glucose Homeostasis and Cardiovascular Risk. Eberhard Standl
Epidemiology of Diabetes, Impaired Glucose Homeostasis and Cardiovascular Risk Eberhard Standl European Heart House Sophia Antipolis Thursday, June 17, 2010 IDF Diabetes Atlas 2009: Global Numbers Still
More informationAPPENDIX B: LIST OF THE SELECTED SECONDARY STUDIES
APPENDIX B: LIST OF THE SELECTED SECONDARY STUDIES Main systematic reviews secondary studies on the general effectiveness of statins in secondary cardiovascular prevention (search date: 2003-2006) NICE.
More informationSupplementary Appendix 2
Supplementary Appendix 2 This appendix has been provided by the authors to give readers additional information about their work. Supplement to: The ACCORD Study Group. Effects of intensive blood-pressure
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationMacrovascular Management. What s next beyond standard treatment?
Macrovascular Management What s next beyond standard treatment? Are Lifestyle Modifications Still Relevant in Diabetic Patients? Diet Omega-6 and omega-3 fatty acids have been shown to improve CVD risk
More informationSTATIN UTILIZATION MANAGEMENT CRITERIA
STATIN UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: HMG Co-A Reductase Inhibitors & Combinations Agents which require prior review: Advicor (niacin extended-release/lovastatin) Crestor (rosuvastatin)(5mg,10mg,
More informationCONTRIBUTING FACTORS FOR STROKE:
CONTRIBUTING FACTORS FOR STROKE: HYPERTENSION AND HYPERCHOLESTEROLEMIA Melissa R. Stephens, MD, FAAFP Associate Professor of Clinical Sciences William Carey University College of Osteopathic Medicine LEARNING
More informationEnvironmental. Vascular / Tissue. Metabolics
Global Risk Reduction--WINS Picking Mom and Dad-2016 Environmental Vascular / Tissue Metabolics Stop smoking-1b Physical activity-1b Weight control-1b Chelation therapy-3c Influenza vaccination-1b Blood
More informationImpact of Chronicity on Lipid Profile of Type 2 Diabetics
Impact of Chronicity on Lipid Profile of Type 2 Diabetics Singh 1, Gurdeep & Kumar 2, Ashok 1 Ph.D. Research Scholar, Department of Sports Science, Punjabi University Patiala, India, Email: drgurdeep_sahni@yahoo.co.in
More informationClinical Investigation and Reports
Clinical Investigation and Reports Cardiovascular Events and Their Reduction With Pravastatin in Diabetic and Glucose-Intolerant Myocardial Infarction Survivors With Average Cholesterol Levels Subgroup
More informationLDL cholesterol and cardiovascular outcomes?
LDL cholesterol and cardiovascular outcomes? Prof Kausik Ray, BSc (hons), MBChB, FRCP, MD, MPhil (Cantab), FACC, FESC Professor of Cardiovascular Disease Prevention St Georges University of London Honorary
More informationHow to Reduce Residual Risk in Primary Prevention
How to Reduce Residual Risk in Primary Prevention Helene Glassberg, MD Assistant Professor of Medicine Section of Cardiology Hospital of the University of Pennsylvania Philadelphia, PA USA Patients with
More informationMetabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk
Metabolic Syndrome Update 21 Marc Cornier, M.D. Associate Professor of Medicine Division of Endocrinology, Metabolism & Diabetes University of Colorado Denver Denver Health Medical Center The Metabolic
More informationDyslipidaemia. Is there any new information? Dr. A.R.M. Saifuddin Ekram
Dyslipidaemia Is there any new information? Dr. A.R.M. Saifuddin Ekram PhD,FACP,FCPS(Medicine) Professor(c.c.) & Head Department of Medicine Rajshahi Medical College Rajshahi-6000 New features of ATP III
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationSTATINS FOR PAD Long - term prognosis
STATINS FOR PAD Long - term prognosis Prof. Pavel Poredos, MD, PhD Department of Vascular Disease University Medical Centre Ljubljana Slovenia DECLARATION OF CONFLICT OF INTEREST No conflict of interest
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More information1. Which one of the following patients does not need to be screened for hyperlipidemia:
Questions: 1. Which one of the following patients does not need to be screened for hyperlipidemia: a) Diabetes mellitus b) Hypertension c) Family history of premature coronary disease (first degree relatives:
More informationStrategies for the prevention of type 2 diabetes and cardiovascular disease
European Heart Journal Supplements (2005) 7 (Supplement D), D18 D22 doi:10.1093/eurheartj/sui025 Strategies for the prevention of type 2 diabetes and cardiovascular disease Jaakko Tuomilehto 1,2,3 *, Jaana
More informationThe Burden of the Diabetic Heart
The Burden of the Diabetic Heart Dr. Ghaida Kaddaha (MBBS, MRCP-UK, FRCP-london) Diabetes Unit Rashid Hospital Dubai U.A.E Risk of CVD in Diabetes Morbidity and mortality from CVD is 2-4 fold higher than
More informationCVD Risk Assessment. Lipid Management in Women: Lessons Learned. Conflict of Interest Disclosure
Lipid Management in Women: Lessons Learned Conflict of Interest Disclosure Emma A. Meagher, MD has no conflicts to disclose Emma A. Meagher, MD Associate Professor, Medicine and Pharmacology University
More informationDiabetes and the Heart
Diabetes and the Heart By Samir Naim Assaad, MD, MRCP(UK), FRCP(Edin), FRCP(Lond) Professor of Medicine & Endocrinology University of Alexandria EGYPT Disclosure None, related to this presentation Road
More informationEFFECT OF GOOD GLYCEMIC CONTROL ON LIPID PROFILE IN TYPE 2 DIABETES MELLITUS PATIENTS IN AL HUSSEIN TEACHING HOSPITAL
Thi-Qar Medical Journal (TQMJ): Vol(5) No(2):2011(39-44) EFFECT OF GOOD GLYCEMIC CONTROL ON LIPID PROFILE IN TYPE 2 DIABETES MELLITUS PATIENTS IN AL HUSSEIN TEACHING HOSPITAL Dr. Akeel bal-yaqobi *, Dr.
More informationTreatment to reduce cardiovascular risk: multifactorial management
Treatment to reduce cardiovascular risk: multifactorial management Matteo Anselmino, MD PhD Assistant Professor San Giovanni Battista Hospital Division of Cardiology, Department of Internal Medicine University
More informationA study on clinical profile of acute coronary syndrome in type 2 diabetes mellitus patients with relevance to HbA1c
Original Research Article A study on clinical profile of acute coronary syndrome in type 2 diabetes mellitus patients with relevance to HbA1c K. Babu Raj 1, G. Sivachandran 2* 1 Reader, 2 Final Year Post
More informationDiabetes Control and Complications in Public Hospitals in Malaysia
ORIGINAL ARTICLE Diabetes Control and Complications in Public Hospitals in Malaysia Mafauzy M. FRCP For the Diabcare-Malaysia Study Group, Health Campus, Universiti Sains Malaysia, 16150 Kubang Kerian,
More information2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc.
2013 Cholesterol Guidelines Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc. Disclosures Speaker Gilead Sciences NHLBI Charge to the Expert Panel Evaluate higher quality
More informationCost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan Nagata-Kobayashi S, Shimbo T, Matsui K, Fukui T
Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan Nagata-Kobayashi S, Shimbo T, Matsui K, Fukui T Record Status This is a critical abstract of an economic evaluation
More informationTotal risk management of Cardiovascular diseases Nobuhiro Yamada
Nobuhiro Yamada The worldwide burden of cardiovascular diseases (WHO) To prevent cardiovascular diseases Beyond LDL Multiple risk factors With common molecular basis The Current Burden of CVD CVD is responsible
More informationChanging lipid-lowering guidelines: whom to treat and how low to go
European Heart Journal Supplements (2005) 7 (Supplement A), A12 A19 doi:10.1093/eurheartj/sui003 Changing lipid-lowering guidelines: whom to treat and how low to go C.M. Ballantyne Section of Atherosclerosis,
More informationIntroduction. Objective. Critical Questions Addressed
Introduction Objective To provide a strong evidence-based foundation for the treatment of cholesterol for the primary and secondary prevention of ASCVD in women and men Critical Questions Addressed CQ1:
More informationCLINICAL. Cholesterol Management of Patients With Diabetes in a Primary Care Practice Based Research Network
Cholesterol Management of Patients With Diabetes in a Primary Care Practice Based Research Network Dawn Fuke, PharmD; Jacquelyn Hunt, PharmD, BCPS; Joseph Siemienczuk, MD; Michael Estoup, PharmD; Michael
More informationLong-Term Complications of Diabetes Mellitus Macrovascular Complication
Long-Term Complications of Diabetes Mellitus Macrovascular Complication Sung Hee Choi MD, PhD Professor, Seoul National University College of Medicine, SNUBH, Bundang Hospital Diabetes = CVD equivalent
More informationHIGH LDL CHOLESTEROL IS NOT AN INDEPENDENT RISK FACTOR FOR HEART ATTACKS AND STROKES
HIGH LDL CHOLESTEROL IS NOT AN INDEPENDENT RISK FACTOR FOR HEART ATTACKS AND STROKES A study published in the British Medical Journal shows that not only is high LDL cholesterol not a risk factor for all-caused
More informationStatistical Fact Sheet Populations
Statistical Fact Sheet Populations At-a-Glance Summary Tables Men and Cardiovascular Diseases Mexican- American Males Diseases and Risk Factors Total Population Total Males White Males Black Males Total
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationNicole Ciffone, MS, ANP-C, AACC Clinical Lipid Specialist
1 Nicole Ciffone, MS, ANP-C, AACC Clinical Lipid Specialist New Cardiovascular Horizons Multidisciplinary Strategies for Optimal Cardiovascular Care February 7, 2015 2 Objectives After participating in
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationCardiovascular Risk Reduction and Other Co-morbidities in Type 2 Diabetes
Cardiovascular Risk Reduction and Other Co-morbidities in Type 2 Diabetes Following this presentation, you will be able to: Describe the relationship between major CV risk factors and CVD outcomes Select
More informationHighlights of the new blood pressure and cholesterol guidelines: A whole new philosophy. Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM
Highlights of the new blood pressure and cholesterol guidelines: A whole new philosophy Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM OSHP 2014 Annual Meeting Oklahoma City, OK April 4, 2014 1 Objectives
More information